The study of my lab responds to multifaceted focus areas, including ubiquitination, cancer signaling, tumor biology, non-coding RNA, CRISPR screening and targeting therapy/immunotherapy, and addresses one of overarching challenges, to develop effective treatments for the most advanced cancers, including triple negative breast cancer, colon, prostate and liver cancer. We will combine multifaceted cutting-edge approaches, including rigorous biochemical, cellular, genetic engineered mouse models (GEMMs), organoid systems and the new high throughput screening platform by integrating a genome-wide platform on both coding and non-coding CRISPR screening system, which allows us for the first time to assess the functions of novel genes at a genome-wide level. By understanding the mechanistic insights and the control of coding genes/non-coding genes in tumorigenesis will not only help us broaden the knowledge of tumor biology in cancer with various origins, but also lay the framework for either coding based- or RNA based-targeting and immunotherapy cancer interventions. Our ultimate goal is to translate all of these into clinics and, hopefully, these works will hold tremendous promise to human patients.